Gilead Sciences

Open: 76.67 Close: 77.48 Change: 0.81

You'll be sorry if you don't use an AI to decide whether to invest in Gilead Sciences.

The game is changing. There is a new strategy to evaluate Gilead Sciences fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Sciences, Gilead, FDA, approve, treatment, patient, Veklury, …

Concept Map

Semantic Network

Stock Summary

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical need. The company provides Biktarvy, Genvoya, Descovy, Descogna, Odefsey,.

Today's Summary

Gilead Sciences to release second quarter 2023 financial results on thursday, august 3, 2023. FDA approves Veklury for treatment of patients with renal impairment.

Today's News

Gilead Sciences to release second quarter 2023 financial results on thursday, august 3, 2023. FDA approves Veklury for treatment of patients with renal impairment. Gilead Sciences has 35 team members, including current Chief Executive Officer, Michael Riordan. Gileads Pediatric Centre of Excellence in Dublin launched in support of children living with HIV. FDA approves Gilead Sciences Remdesivir for treatment of patients with severe renal impairment, including those on dialysis. FDA approved supplemental new drug application for using Veklury in COVID-19 patients. Gilead Sciences has entered into public-private collaborations with the Clinton Health Access Initiative (CHAI) and the Penta ID network to expedite the development and marketing of dispersible HIV treatments for the paediatric population. Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus. Remdesivir was originally created and developed by Gilead Sciences in 2009, to treat hepatitis C and respiratory syncytial virus (RSV) In February 2016, orphan designation (EU/3/16/1615) was granted by the European Commission to GileAD Sciences International Ltd, United Kingdom, for remdesiviral for the treatment of Ebola virus disease. Gilead Sciences is a biopharmaceutical company that discovers, develops, commercializes and commercializes innovative therapeutics in areas of unmet medical need. The company trades on the NASDAQ under the ticker symbol. Gilead Sciences, Inc. (GILD) Stock Over or Undervalued? Friday, July 14, 2023 01:00 PM | InvestorsObserver Analysts Mentioned in this article GILD 0.38% 69 See GILD Report Gileads Inc. gilead sciences. Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023. Analyst Consensus: Buy Stock Forecasts: Buy stock Forecasts. Gilead Sciences announced the US Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for remdesivir (Veklury) for patients with severe renal impairment, including those on dialysis.

Stock Profile

"Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California."

Keywords

Are looking for the most relevant information about Gilead Sciences? Investor spend a lot of time searching for information to make investment decisions in Gilead Sciences. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Sciences, Gilead, FDA, approve, treatment, patient, Veklury, and the most common words in the summary are: gilead, science, inc, job, stock, gild, company, . One of the sentences in the summary was: Gilead Sciences to release second quarter 2023 financial results on thursday, august 3, 2023. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #gilead #science #inc #job #stock #gild #company.